Mordechai Muszkat

List of Publications by Year
in descending order

76 papers	1,967 citations	236833 25 h-index	302012 39 g-index
80 all docs	80 docs citations	80 times ranked	2646 citing authors

#	Article	IF	Citations
1	Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study. CNS Drugs, 2021, 35, 305-316.	2.7	14
2	Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 601-610.	1.0	9
3	Association Between Use of Pharmacokineticâ€Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Caseâ€Control Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1526-1536.	2.3	38
4	Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Scientific Reports, 2021, 11, 22777.	1.6	159
5	Gender differences in the effect of medical humanities program on medical studentsâ€™ empathy: a prospective longitudinal study. BMC Medical Education, 2020, 20, 413.	1.0	4
6	Fasting-Induced Natriuresis and SGLT: A New Hypothesis for an Old Enigma. Frontiers in Endocrinology, 2020, 11, 217.	1.5	13
7	The effect of multidrug exposure on neurological manifestations in carbamazepine intoxication: a nested case-control study. BMC Pharmacology & Toxicology, 2020, 21, 47.	1.0	8
8	Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS). CNS Drugs, 2019, 33, 1223-1228.	2.7	22
9	Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Israel Journal of Health Policy Research, 2019, 8, 19.	1.4	28
10	Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Populationâ€Based Nested Caseâ€Control Study. Pharmacotherapy, 2019, 39, 690-696.	1.2	7
11	Calcium Channel Blockers and the Risk for Lung Cancer: A Population-Based Nested Case-Control Study. Annals of Pharmacotherapy, 2019, 53, 445-452.	0.9	16
12	Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. Journal of Thrombosis and Thrombolysis, 2019, 47, 590-595.	1.0	15
13	Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis. Drug Safety, 2019, 42, 529-538.	1.4	69
14	The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies. Drug Safety, 2018, 41, 555-564.	1.4	32
15	Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis. Annals of Pharmacotherapy, 2018, 52, 1135-1142.	0.9	39
16	Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	49
17	Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia. Drug Safety, 2018, 41, 239-252.	1.4	71
18	Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients. Journal of Thrombosis and Thrombolysis, 2018, 46, 521-527.	1.0	19

#	Article	IF	Citations
19	Managing Direct Oral Anticoagulants in Patients With Antiepileptic Medication. Canadian Journal of Cardiology, 2018, 34, 1534.e1-1534.e3.	0.8	11
20	Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. Journal of Cardiac Failure, 2018, 24, 533-536.	0.7	14
21	The hemodynamic response to constant dobutamine infusion. Pharmacogenetics and Genomics, 2018, 28, 139-146.	0.7	2
22	Challenges in the Diagnosis of Cytomegalovirus Colitis in a Presumed Immunocompetent Patient: Interpretation of Clinical Condition, Tissue, and Serum Cytomegalovirus Polymerase Chain Reaction Findings. Israel Medical Association Journal, 2018, 20, 194-196.	0.1	4
23	Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 Inhibitors. Israel Medical Association Journal, 2018, 20, 513-516.	0.1	8
24	Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. Molecular Diagnosis and Therapy, 2017, 21, 75-83.	1.6	7
25	Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure. Chest, 2016, 149, 1516-1524.	0.4	43
26	Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine. Pharmacogenetics and Genomics, 2015, 25, 555-563.	0.7	5
27	Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise. Physiological Genomics, 2015, 47, 400-406.	1.0	6
28	The effect of medical studentsâ€™ gender, ethnicity and attitude towards poetry-reading on the evaluation of a required, clinically-integrated poetry- based educational intervention. BMC Medical Education, 2014, 14, 188.	1.0	3
29	Response to Is Creatine Kinase the Intrinsic Factor of Smooth Muscle Enhancing Vascular Contractility in Subjects of African Ancestry?. Hypertension, 2013, 62, .	1.3	0
30	Blacks Have a Greater Sensitivity to Î± ₁ -Adrenoceptorâ€“Mediated Venoconstriction Compared With Whites. Hypertension, 2013, 61, 915-920.	1.3	21
31	Variation in the Î±2A adrenoceptor gene and the effect of dexmedetomidine on plasma insulin and glucose. Pharmacogenetics and Genomics, 2013, 23, 479-486.	0.7	13
32	A polymorphism in the protein kinase C gene PRKCB is associated with Î±2-adrenoceptor-mediated vasoconstriction. Pharmacogenetics and Genomics, 2013, 23, 127-134.	0.7	5
33	The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting Î²1 adrenergic receptor antagonist esmolol in healthy individuals. Pharmacogenetics and Genomics, 2013, 23, 25-28.	0.7	10
34	Catecholamine pathway gene variation is associated with norepinephrine and epinephrine concentrations at rest and after exercise. Pharmacogenetics and Genomics, 2012, 22, 254-260.	0.7	18
35	Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. European Journal of Clinical Pharmacology, 2012, 68, 617-627.	0.8	8
36	CYP2A6 genetic variation and dexmedetomidine disposition. European Journal of Clinical Pharmacology, 2012, 68, 937-942.	0.8	42

#	Article	IF	Citations
37	Effects of CYP4F2 Polymorphism on Response to Warfarin During Induction Phase: A Prospective, Open-Label, Observational Cohort Study. Clinical Therapeutics, 2012, 34, 811-823.	1.1	22
38	Risk Factors for Prescribing and Transcribing Medication Errors among Elderly Patients during Acute Hospitalization. Drugs and Aging, 2011, 28, 491-500.	1.3	15
39	Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans. Pharmacogenetics and Genomics, 2011, 21, 171-178.	0.7	25
40	Independent regulation of Î±1 and Î±2 adrenergic receptor-mediated vasoconstriction in vivo. Journal of Hypertension, 2011, 29, 251-256.	0.3	14
41	Genetic Variations in the Î± _{2A} -Adrenoreceptor Are Associated With Blood Pressure Response to the Agonist Dexmedetomidine. Circulation: Cardiovascular Genetics, 2011, 4, 179-187.	5.1	27
42	Desensitization of vascular response in vivo: contribution of genetic variation in the Î±2B-adrenergic receptor subtype. Journal of Hypertension, 2010, 28, 278-284.	0.3	23
43	Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: An open-label, prospective study of long-term administration in adults. Clinical Therapeutics, 2010, 32, 347-356.	1.1	4
44	Effects of variation in the human Î±_{2A}â€•and Î±_{2C}â€adrenoceptor genes on cognitive tasks and pain perception. European Journal of Pain, 2010, 14, 154-159.	1.4	29
45	Teaching empathy through poetry: a clinically based model. Medical Education, 2010, 44, 503-503.	1.1	25
46	GRK5 Gln41Leu polymorphism is not associated with sensitivity to Î²₁-adrenergic blockade in humans. Pharmacogenomics, 2009, 10, 1581-1587.	0.6	21
47	Factors Associated with Bleeding in Elderly Hospitalized Patients Treated with Enoxaparin Sodium. Drugs and Aging, 2009, 26, 77-85.	1.3	17
48	Ethnic and Genetic Determinants of Cardiovascular Response to the Selective Î± 2 -Adrenoceptor Agonist Dexmedetomidine. Hypertension, 2008, 51, 406-411.	1.3	37
49	Genetic variants in the Î±2C-adrenoceptor and G-protein contribute to ethnic differences in cardiovascular stress responses. Pharmacogenetics and Genomics, 2008, 18, 743-750.	0.7	22
50	Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenetics and Genomics, 2008, 18, 895-902.	0.7	48
51	Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamideâ€™s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein. Anesthesiology, 2008, 109, 1092-1099.	1.3	31
52	Effect of the Î±2C-adrenoreceptor deletion322â€“325 variant on sympathetic activity and cardiovascular measures in healthy subjects. Journal of Hypertension, 2007, 25, 763-771.	0.3	15
53	Warfarin metabolism and anticoagulant effect: A prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clinical Therapeutics, 2007, 29, 427-437.	1.1	37
54	Interethnic Differences in Drug Response: The Contribution of Genetic Variability in Î² Adrenergic Receptor and Cytochrome P4502C9. Clinical Pharmacology and Therapeutics, 2007, 82, 215-218.	2.3	12

#	Article	IF	Citations
55	Variations in the Î±2A-adrenergic receptor gene and their functional effects. Clinical Pharmacology and Therapeutics, 2006, 79, 173-185.	2.3	28
56	Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1012-1018.	1.3	78
57	Variation in the ??2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo. Pharmacogenetics and Genomics, 2005, 15, 407-414.	0.7	31
58	??2B Adrenergic receptor 301???303 deletion polymorphism and vascular ??2 adrenergic receptor response. Pharmacogenetics and Genomics, 2005, 15, 23-28.	0.7	14
59	Pharmacogenetics and Response to Î²-adrenergic Receptor Antagonists in Heart Failure*. Clinical Pharmacology and Therapeutics, 2005, 77, 123-126.	2.3	12
60	Alpha 2 -Adrenergic Receptorâ€“Induced Vascular Constriction in Blacks and Whites. Hypertension, 2004, 43, 31-35.	1.3	23
61	Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: An open-label, uncontrolled trial. Clinical Therapeutics, 2004, 26, 407-414.	1.1	17
62	Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clinical Pharmacology and Therapeutics, 2003, 73, 253-263.	2.3	174
63	Response to influenza vaccination in community and in nursing home residing elderly: relation to clinical factors. Experimental Gerontology, 2003, 38, 1199-1203.	1.2	22
64	Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine, 2003, 21, 1180-1186.	1.7	51
65	Factors associated with mortality among elderly patients with hypothermia. American Journal of Medicine, 2002, 113, 234-237.	0.6	10
66	Major Bleeding Caused by Warfarin in a Genetically Susceptible Patient. Pharmacotherapy, 2002, 22, 97-101.	1.2	15
67	The evaluation of pleural effusions in patients with heart failure. American Journal of Medicine, 2001, 111, 375-378.	0.6	35
68	Compound Cardiac Toxicity of Oral Erythromycin and Verapamil. Annals of Pharmacotherapy, 2001, 35, 1396-1399.	0.9	33
69	Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics and Genomics, 2001, 11, 587-596.	5.7	53
70	Glucose-6-phosphate dehydrogenase deficiency is associated with increased initial clinical severity of acute viral hepatitis A. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 1239-1243.	1.4	30
71	Co-occurrence of Hepatocellular Carcinoma and Lymphoma in Patients with Hepatitis C Virus Cirrhosis. Journal of Clinical Gastroenterology, 2001, 32, 368-369.	1.1	13
72	Mefloquine-Induced Acute Hepatitis. Pharmacotherapy, 2000, 20, 1517-1519.	1.2	15

#	Article	IF	Citations
73	Natural course of insulin edema. Journal of Endocrinological Investigation, 2000, 23, 187-188.	1.8	29
74	Corticosteroid-induced glaucoma attributable to an adrenocorticotropin-secreting malignant carcinoid tumor of the thymus. American Journal of Ophthalmology, 1999, 128, 100-101.	1.7	10
75	Reflective Clinical Reasoning Tool (REâ€CREATE). Medical Education, 0, , .	1.1	0
76	Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance. Clinical Pharmacokinetics, 0, , .	1.6	1